help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yokomura, K.
Right arrow Articles by Nakamura, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yokomura, K.
Right arrow Articles by Nakamura, H.
The Journal of Clinical Endocrinology & Metabolism Vol. 88, No. 12 5704-5709
Copyright © 2003 by The Endocrine Society

Increased Expression of the 25-Hydroxyvitamin D3-1{alpha}-Hydroxylase Gene in Alveolar Macrophages of Patients with Lung Cancer

Koushi Yokomura, Takafumi Suda, Shigekazu Sasaki, Naoki Inui, Kingo Chida and Hirotoshi Nakamura

Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan

Address all correspondence and requests for reprints to: Hirotoshi Nakamura, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu 431-3192, Japan. E-mail: hirotosh{at}hama-med.ac.jp.


   Abstract
Top
 Abstract
Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
25-Hydroxyvitamin D3-1{alpha}-hydroxylase (1{alpha}-hydroxylase) plays a central role in calcium metabolism by synthesizing the active hormone 1{alpha},25-dihydroxyvitamin D3 in the kidney. Its increased expression in the extrarenal tissues has been found in alveolar macrophages in sarcoidosis but not in any other pathological conditions. We found that 1{alpha}-hydroxylase-mRNA in alveolar macrophages measured by semiquantitative RT-PCR was 2-fold greater in patients with lung cancer than in control subjects (0.61 ± 0.20 vs. 0.34 ± 0.11, respectively; P < 0.0001). When the clinical stages of lung cancer were divided into early (stage IA–IIIA) and advanced (stage IIIB and IV) and the expression of 1{alpha}-hydroxylase gene was compared among the control, early, and advanced groups, the advanced group showed the highest expression, followed by the early group, then the control group (0.34 ± 0.11, 0.52 ± 0.11, and 0.69 ± 0.23 for control, early, and advanced groups, respectively; P < 0.0001). The 1{alpha}-hydroxylase-mRNA level was well correlated with serum 1{alpha},25-dihydroxylase D3 concentration and the 1{alpha},25-dihydroxylase D3 to 25-hydroxyvitamin D3 ratio, but none of the findings related to calcium metabolism among the patients with lung cancer. Increased local production of 1{alpha},25-dihydroxyvitamin D3 may be associated with the pathological conditions, such as immunosuppression, in lung cancer.


   Introduction
Top
 Abstract
 Introduction
Subjects and Methods
 Results
 Discussion
 References
 
25-HYDROXYVITAMIN D3-1{alpha}-HYDROXYLASE (1{alpha}-hydroxylase) is the mitochondrial cytochrome P450 enzyme that converts 25-hydroxyvitamin D3 [25-(OH) D3] to 1{alpha},25-dihydroxyvitamin D3 [1,25-(OH)2 D3] (1, 2, 3, 4). The enzyme activity of 1{alpha}-hydroxylase is the key determinant to the synthesis of the active hormone 1,25-(OH)2 D3, which plays an important role in not only calcium metabolism but also cell differentiation and proliferation (2, 3, 4). Actually, 1,25-(OH)2 D3 has been shown to have potent immunosuppressive properties (5). Under normal circumstances, the hydroxylation of 25-(OH) D3 is exclusively conducted in the proximal renal tubule. Certain pathological conditions, such as sarcoidosis and other granulomatous diseases, cause extrarenal expression of this enzyme, resulting in possible hypercalcemia and hypercalciuria (6, 7, 8). Several investigators have recently isolated rat, mouse, and human 1{alpha}-hydroxylase cDNA (9, 10, 11, 12, 13). Using the semiquantitative RT-PCR technique, we identified, for the first time, the expression of the 1{alpha}-hydroxylase gene in human alveolar macrophages (AMs) (14). We also demonstrated that the 1{alpha}-hydroxylase-mRNA level in AMs obtained from patients with sarcoidosis was significantly higher than the level obtained from the control patients with other pulmonary diseases (14). The 1{alpha}-hydroxylase-mRNA level was well correlated with the disease activity of sarcoidosis, serum ionized calcium, and the ratio of 1,25-(OH)2 D3 to 25-(OH) D3. The function of increased 1{alpha}-hydroxylase in sarcoidosis is uncertain, but our findings raised the possibility that 1,25-(OH)2 D3 might provide a compensatory mechanism to inhibit the inflammatory process, suppressing the activated helper T cell proliferation and cytokine production in sarcoid granulomas (15, 16, 17).

In the present study, we found the significantly increased expression of 1{alpha}-hydroxylase in AMs of patients with lung cancer. The level of 1{alpha}-hydroxylase-mRNA was well correlated to serum 1,25-(OH)2 D3 and the ratio of serum 1,25-(OH)2 D3 to 25-(OH) D3 but not to calcium metabolism. The enzyme expression increased depending on the progress in the clinical stage.


   Subjects and Methods
Top
 Abstract
 Introduction
 Subjects and Methods
Results
 Discussion
 References
 
Subjects

Twenty-two consecutive patients with lung cancer (14 men and eight women, ages 44–83 yr) who underwent bronchoalveolar lavage (BAL) between October 1999 and June 2003 were included in this study. The diagnosis of lung cancer was histologically established on biopsy samples of lung tissues. The clinical features of these patients are shown in Table 1Go. The histological types of lung cancer were adenocarcinoma in 12 patients, small-cell carcinoma in five patients, and squamous cell carcinoma in five patients. Their clinical stages were stage IA in five patients, stage IB in one patient, stage IIA in one patient, stage IIIA in two patients, stage IIIB in 10 patients, and stage IV in three patients. BAL was performed before any medical treatment in 19 patients, but patients no. 14, 15, and 20 had received chemotherapy with or without radiotherapy before BAL. None of the patients had received medications that might affect calcium metabolism. There were nine smokers and 13 nonsmokers. For controls, 13 patients with other pulmonary disorders (five patients with idiopathic interstitial pneumonia, four patients with pulmonary emphysema, and four patients with organizing pneumonia) and five normal healthy volunteers were studied. Because no significant difference was observed between the two groups in any experimental measurements, as shown in Results, all subjects were combined in a control group (16 men and two women, ages 30–77 yr, six smokers and 12 nonsmokers). The study protocol was approved by our institutional review board for human research. Informed consent was given by each subject.


View this table:
[in this window]
[in a new window]
  		TABLE 1. Clinical characteristics of patients with lung cancer

 
BAL procedures, preparation of BAL cells, and purification of AMs

BAL was performed as previously reported (18). Briefly, both the upper and lower respiratory tracts were anesthetized with topically administered lidocaine. A BF-240 Olympus fiberoptic bronchoscope (Olympus Co., Tokyo, Japan) was passed transorally and wedged in a segmental or subsegmental bronchus. Three 50-ml aliquots of prewarmed sterile 0.9% saline were instilled, and the returns were gently aspirated through the side channel of the bronchoscope (19). Bronchoalveolar cells were separated by centrifugation at 500 x g for 10 min at 4 C and washed with PBS. The total cell count was determined using a hemocytometer. The BAL cells were resuspended in the culture medium at a density of 1 x 106 cells/ml. A differential cell count was performed on cytocentrifuged smears stained with Wright-Giemsa. As in the previous study (14), purified AMs were obtained by the method of removing nonadherent cells (20). The cells were plated into dishes coated with fetal calf serum and incubated at 37 C in 5% CO2 for 2 h. All adherent cells were macrophages.

Measurement of serum markers of calcium metabolism

Fasting blood samples were collected at the time of bronchoscopy. The serum calcium level, which was measured by automated methods, was corrected for the serum albumin level. The serum levels of PTH and PTHrP were determined by chemiluminescent immunoassay (normal range, 10–65 ng/l) and immunoradiometric assay (normal range, < 0.6 pmol/l), respectively. The serum ionized calcium level was measured using an ion-selective electrode (normal range, 1.20–1.35 mmol/l) (21). The serum levels of 1,25-(OH)2 D3 (normal range, 26–169 pmol/l) and 25-(OH) D3 (normal range, 25–137 nmol/l) were measured by RIA and competitive protein-binding analysis (22), respectively.

RNA isolation and RT-PCR

Total RNA was extracted from BAL cells using the acid guanidinium thiocyanate-phenol-chloroform technique (23). Two micrograms were used for the first-standard cDNA synthesis with Moloney murine leukemia virus reverse transcriptase (Life Technologies, Rockville, MD) and random hexanucleotide. After terminating the reaction by heating at 70 C for 10 min, the reaction mixture was diluted 5-fold with distilled water.

The level of human 1{alpha}-hydroxylase-mRNA was measured by PCR amplification. PCR was performed in 50 µl reaction mediums containing 5 µl of cDNA solution, 0.2 mM of forward and reverse primers, 0.2 mM of deoxynucleotide triphosphates, and 1.25 U of Pyrobest DNA polymerase (Takara Shuzo Co., Tokyo, Japan). After 3 min of initial denaturation at 96 C, amplification was performed in a DNA Thermal Cycler (Perkin-Elmer, Norwalk, CT) for 42 cycles with 30-sec denaturing at 96 C, 40-sec annealing at 60 C, and 1-min extension at 72 C. We designed the sequences of the primers spanning an intron of each genome, 5'-GTGTCCACGCTGTTGACCATG-3' and 5'-GAATTTCCAGGTACCACAGG-3'. When semiquantitative RT-PCR was performed, PCR amplification was carried out for 30–42 cycles for 1{alpha}-hydroxylase and for 28–38 cycles for human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the control for gene expression. The PCR products were separated on 1% agarose gel by electrophoresis, stained with ethidium bromide, and visualized. We confirmed the linearity of the PCR products up to 36 cycles for 1{alpha}-hydroxylase and GAPDH; the values obtained were plotted against the numbers of cycles. Each best-fit straight line was obtained and extrapolated back to zero cycle. The intercepts at the zero cycle were used to determine the relative abundance of both mRNAs, and the value for 1{alpha}-hydroxylase was normalized to GAPDH. The RT-PCR product of 1{alpha}-hydroxylase was confirmed by Southern blot analysis as described previously (14).

Statistical analysis

All values were analyzed with StatView J 4.5-software (SAS Institute, Cary, NC). The BAL cells, serum markers of calcium metabolism, and 1{alpha}-hydroxylase mRNA level were compared among groups by ANOVA, and when ANOVA showed significant difference, Fisher’s protected least significant difference test was performed. P < 0.05 was considered significant. The correlation between relative intensity of the 1{alpha}-hydroxylase mRNA level and markers of calcium metabolism were evaluated using the Pearson’s correlation coefficient. All continuous values are expressed as means ± SD.


   Results
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
Discussion
 References
 
Expression of the 1{alpha}-hydroxylase gene in AMs obtained from patients with lung cancer

Between the patients with lung cancer and the control subjects, there were no significant difference in the total counts of BAL cells obtained and the percentages of macrophages and lymphocytes (Table 2Go).


View this table:
[in this window]
[in a new window]
  		TABLE 2. BAL and laboratory findings of patients with lung cancer and controls

 
The 1{alpha}-hydroxylase-mRNA was detected in AMs obtained from every subject. The relative intensity of its level measured by semiquantitative RT-PCR is shown in Fig. 1Go. No difference was found between five normal healthy volunteers and 13 patients with other pulmonary diseases; therefore, we combined them in a control group. The expression of 1{alpha}-hydroxylase mRNA in patients with lung cancer was approximately 2-fold greater than that in the controls (0.61 ± 0.20 vs. 0.34 ± 0.11, P < 0.0001).



View larger version (20K):
[in this window]
[in a new window]
  		FIG. 1. Difference in the expression of 1{alpha}-hydroxylase mRNA in AMs between the patients with lung cancer and controls. In the controls, shaded circles represent normal healthy volunteers, whereas open circles represent patients with other pulmonary diseases. There was no difference in the expression of 1{alpha}-hydroxylase mRNA between the normal healthy volunteers and control patients with other pulmonary diseases.

 
Correlation of the 1{alpha}-hydroxylase-mRNA level and the findings concerned with lung cancer

When we compared the 1{alpha}-hydroxylase-mRNA expression level among the clinical stages of lung cancer, it was difficult to make a clear conclusion because the number of the patients in each group was small, although a tendency might be seen that the enzyme expression increased with advancing clinical stage (Fig. 2AGo). Therefore, we divided the clinical stage into early and advanced stage, according to the clinical classification for operability (24). Early lung cancer includes stage IA–IIIA, whereas advanced lung cancer includes stage IIIB and IV. When the expression of 1{alpha}-hydroxylase gene was compared among control, early, and advanced groups, the advanced group had the highest mRNA levels, followed by the early group, and then the control group (Fig. 2BGo). No difference was observed among the pathological types of lung cancer (Fig. 2CGo), or between genders, smoking habits, or prior treatments (data not shown).



View larger version (22K):
[in this window]
[in a new window]
  		FIG. 2. Comparison of the expression of the 1{alpha}-hydroxylase gene among the patients with lung cancer between their clinical stages (A and B) and their pathological types (C). The early stage of lung cancer includes stages IA–IIIA, and the advanced stage of lung cancer includes stages IIIB and IV. In the controls, shaded circles represent normal healthy volunteers, whereas open circles represent patients with other pulmonary diseases. Horizontal lines with figures represent mean values for each group of circles.

 
Relationship between the 1{alpha}-hydroxylase-mRNA level and calcium metabolism

The 1{alpha}-hydroxylase-mRNA level showed a significant correlation with the serum 1,25-(OH)2 D3 concentration (P = 0.03, Fig. 3AGo) and with the ratio of 1,25-(OH)2 D3 to 25-(OH) D3 (P = 0.0008, Fig. 3BGo) among the patients with lung cancer. The correlation became much higher when analyzed in all 40 patients, including patients with lung cancer, control patients with other pulmonary diseases, and healthy volunteers (Fig. 3Go, A and B). As shown in Table 2Go, none of the findings related to calcium metabolism, such as serum calcium, ionized calcium, PTH, PTHrP, 25-(OH) D3 and 1,25-(OH)2 D3, were significantly different between the lung cancer group and the controls. However, the ratio of 1,25-(OH)2 D3 to 25-(OH) D3 was significantly higher in the patients with lung cancer than control subjects, suggesting that the enzyme was functional. When compared among control, early, and advanced groups, the serum 1,25-(OH)2 D3 level tended to be higher, although not significant, in the advanced group; and the ratio of 1,25-(OH)2 D3 to 25-(OH) D3 was significantly higher in the advanced lung cancer group than other groups (Fig. 4BGo).



View larger version (22K):
[in this window]
[in a new window]
  		FIG. 3. Correlation of the expression of the 1{alpha}-hydroxylase gene and the serum concentration of 1,25-(OH)2 D3 (A) and the ratio of 1,25-(OH)2 D3 to 25-(OH) D3 (B). The closed circles, shaded circles, and open circles represent patients with lung cancer, normal healthy subjects, and control patients with other pulmonary diseases, respectively. The solid lines indicate the regression lines among the patients with lung cancer only; the broken lines indicate the regression lines for all subjects, including patients with lung cancer and control subjects.

 


View larger version (13K):
[in this window]
[in a new window]
  		FIG. 4. Comparison of the serum concentration of 1,25-(OH)2 D3 (A) and the ratio of 1,25-(OH)2 D3 to 25-hydroxyvitamin D3 (B) among the clinical stages. In the controls, shaded circles represent normal healthy volunteers, whereas open circles represent patients with other pulmonary diseases. There was no difference in the data between normal healthy volunteers and patients with other pulmonary diseases.

 

   Discussion
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
References
 
In the previous study, we demonstrated the presence of 1{alpha}-hydroxylase gene expression in human AMs and observed a significant correlation between the 1{alpha}-hydroxylase gene expression and the disease activity in patients with sarcoidosis (14). In the present study, using the same semiquantitative RT-PCR technique, we found that the expression of 1{alpha}-hydroxylase mRNA in AMs was significantly enhanced in patients with lung cancer. Except for sarcoidosis, there are few reports demonstrating the enhanced expression of 1{alpha}-hydroxylase gene in human extrarenal tissues under pathological conditions.

A significant correlation was obtained between the 1{alpha}-hydroxylase-mRNA level in AMs of patients with lung cancer and their serum 1,25-(OH)2 D3 concentration and the 1,25-(OH)2 D3 to 25-(OH) D3 ratio. This suggests that 1{alpha}-hydroxylase in AMs in patients does actually function to catalyze the synthesis of active vitamin D3 sterol. In contrast to sarcoidosis, however, the increased expression of this enzyme did not correlate with serum total and ionized calcium concentrations. The enhancement of 1{alpha}-hydroxylase might not be adequate to induce an increase in serum calcium because the patients with sarcoidosis in our previous study showed a 6-fold increase in 1{alpha}-hydroxylase-mRNA, whereas the patients with lung cancer in the present study manifested only twice as much of the enzyme level as the controls.

It is of interest that the 1{alpha}-hydroxylase gene expression tended to be higher in advanced stages of lung cancer. When we classified the patients based on their clinical stages from IA–IV, we did not obtain a significant difference in the 1{alpha}-hydroxylase-mRNA level among the groups because of the insufficient number of patients. The patients were, therefore, divided into two groups, early and advanced; the early group included stages IA–IIIA, and the advanced group included stages IIIB and IV. The basis of this classification is that patients with non-small-cell lung cancer with clinical stages IA–IIIA are usually considered to be operable, whereas patients with stages IIIB and IV are not. The mRNA level of 1{alpha}-hydroxylase was the highest in the advanced group and lowest in the control group (Fig. 2BGo). In addition, the advanced group showed a significantly higher level of the 1,25-(OH)2 D3 to 25-(OH) D3 ratio and a tendency to have a higher 1,25-(OH)2 D3 concentration than the control group (Fig. 4Go).

Although 1{alpha}-hydroxylase is almost exclusively expressed in the kidney under normal circumstances (2, 3, 4, 25), the presence of this enzyme in some extrarenal cells, such as macrophages and keratinocytes, has been suggested under some pathological conditions by the assay of the enzyme activity (2, 4, 25). After cloning of the 1{alpha}-hydroxylase cDNA, the detection of the extrarenal expression of this enzyme at the mRNA and protein levels has become possible. We demonstrated 1{alpha}-hydroxylase-mRNA in human AMs for the first time (14). Zehnder et al. (26) synthesized a specific antibody against an antigenic region of the mouse 1{alpha}-hydroxylase amino acid sequence and examined the extrarenal expression of this enzyme. Their immunohistochemical study confirmed the discrete expression of 1{alpha}-hydroxylase in several human tissues including skin (basal keratinocytes), lymph nodes (granulomata), colon (epithelial cells and parasympathetic ganglia), pancreas (islets), adrenal medulla, brain (cerebellum and cerebral cortex), and placenta (decidual and trophoblastic cells). Thus, the expression of 1{alpha}-hydroxylase is more widespread than previously suggested, but the function of this enzyme in these extrarenal tissues is unknown at present.

It may be intriguing to consider the functional relevance of 1{alpha}-hydroxylase enhancement in lung cancer. Augmented enzyme expression did not relate to the serum calcium level but did relate to the increased synthesis of circulating 1,25-(OH)2 D3, which probably reflected the increased local production induced by the enhanced 1{alpha}-hydroxylase activity in AMs. It was reported that 1,25-(OH)2 D3 plays immunomodulatory roles in a variety of immune responses. In vitro studies have revealed that 1,25-(OH)2 D3 inhibits activated T cell functions, resulting in suppression of cytokine synthesis and antibody-stimulating activities (2, 3, 4, 5, 27). 1,25-(OH)2 D3 has also been demonstrated to inhibit natural killer cell activity at a physiological concentration (28) and suppress the proliferation and maturation of antigen presentation cells (29, 30). Moreover, administration of 1,25-(OH)2 D3 in vivo diminished the TNF{alpha} and interferon (IFN)-{gamma} production by Th1 cells, resulting in prevention of experimental autoimmune encephalomyelitis (31). Vitamin D analogs have been effectively used to prolong transplant survival in animal models of transplantation (32, 33). These findings suggest that 1,25-(OH)2 D3 is a potent immunosuppressive agent and raise the possibility that the locally synthesized 1,25-(OH)2 D3 in AMs function for immunosuppression in lung cancer. It was reported that patients with lung cancer exhibit dysfunction of the immune system, such as the impairment of tumor-specific immune response during the initial stage of tumor growth and generalized immunodeficiency during the late stage of tumor development (34, 35). Alterations in T cell functions occur in patients with various cancers including melanoma (36), renal cell carcinoma (37), cervical cancer (38), and others (39). In addition, mice bearing slowly progressive tumors induced by carcinogen demonstrated significantly diminished functions of T cells and natural killer cells and impaired capacity to produce Th1 cytokines (40).

The mechanism of how 1{alpha}-hydroxylase is regulated in AMs of patients with lung cancer remains to be elucidated. It is known that renal 1{alpha}-hydroxylase synthesis is tightly regulated by the concentration of serum calcium, PTH, and 1,25-(OH)2 D3 (2, 3, 4, 25, 41). In contrast, extrarenal synthesis of 1{alpha}-hydroxylase by macrophages does not respond to these regulatory influences, but rather, it is sensitive to immune signals, such as IFN-{gamma}, TNF{alpha}, and lipopolysaccharide (42, 43, 44, 45, 46). In patients with malignancy, overproduction of various cytokines, including IFN-{gamma}, TNF{alpha}, IL-2, and TGF-ß, have been identified either by cancer cells or host immune cells (34, 35). Their production was most evident in patients with advanced stages of cancer. Although we have currently no data indicating augmentation of these cytokines in BAL, it is possible that they may play a role in enhanced expression of 1{alpha}-hydroxylase in AMs.

In conclusion, the present study demonstrated that patients with lung cancer have increased expression of 1{alpha}-hydroxylase in AMs, which correlates with serum 1,25-(OH)2 D3 concentration. It is possible that increased production of 1,25-(OH)2 D3 may be associated with immunosuppression in lung cancer.


   Footnotes
 
Abbreviations: AM, Alveolar macrophage; BAL, bronchoalveolar lavage; {alpha}-hydroxylase, 25-hydroxyvitamin D3-1{alpha}-hydroxylase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IFN, interferon; 11,25-(OH)2 D3, 1{alpha},25-dihydroxyvitamin D3; 25-(OH) D3, 25-hydroxyvitamin D3.

Received March 27, 2003.

Accepted September 5, 2003.


   References
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 

  1. Fraser DR, Kodicek E 1970 Unique biosynthesis by kidney of a biological active vitamin D metabolite. Nature 228:764–766[CrossRef][Medline]
  2. Reichel H, Koeffler HP, Norman AW 1989 The role of the vitamin D endocrine system in health and disease. N Engl J Med 320:980–991[Medline]
  3. Jones G, Strugnell SA, DeLuca HF 1998 Current understanding of the molecular actions of vitamin D. Physiol Rev 78:1193–1231[Abstract/Free Full Text]
  4. Feldman D, Glorieux FH, Pike JW 1997 Vitamin D. San Diego: Academic Press
  5. Hewison M 1992 Vitamin D and the immune system. J Endocrinol 132:173–175[Abstract/Free Full Text]
  6. Adams JS, Sharma OP, Gacad MA, Singer FR 1983 Metabolism of 25- hydroxyvitamin D3 by cultured pulmonary alveolar macrophages in sarcoidosis. J Clin Invest 72:1856–1860
  7. Papapoulos SE, Clemens TL, Fraher LJ, Lewin IG, Sandler LM, O’Riordan JL 1979 1, 25-dihydroxycholecalciferol in the pathogenesis of the hypercalcaemia of sarcoidosis. Lancet 1:627–630[Medline]
  8. Adams JS 1989 Vitamin D metabolite-mediated hypercalcemia. Endocrinol Metab Clin North Am 18:765–778[Medline]
  9. St-Arnaud R, Messerlian S, Moir JM, Omdahl JL, Glorieux FH 1997 The 25-hydroxyvitamin D 1-{alpha}-hydroxylase gene maps to the pseudovitamin D-deficiency rickets (PDDR) disease locus. J Bone Miner Res 12:1552–1559[CrossRef][Medline]
  10. Takeyama K, Kitanaka S, Sato T, Kobori M, Yanagisawa J, Kato S 1997 25-Hydroxyvitamin D3 1{alpha}-hydroxylase and vitamin D synthesis. Science 277:1827–1830[Abstract/Free Full Text]
  11. Fu GK, Lin D, Zhang MY, Bikle DD, Shackleton CH, Miller WL, Portale AA 1997 Cloning of human 25-hydroxyvitamin D-1 {alpha}-hydroxylase and mutations causing vitamin D-dependent rickets type 1. Mol Endocrinol 11:1961–1970[Abstract/Free Full Text]
  12. Kato S, Yanagisawa J, Murayama A, Kitanaka S, Takeyama K 1998 The importance of 25-hydroxyvitamin D3 1 {alpha}-hydroxylase gene in vitamin D-dependent rickets. Curr Opin Nephrol Hypertens 7:377–783[Medline]
  13. Kitanaka S, Takeyama K, Murayama A, Sato T, Okumura K, Nogami M, Hasegawa Y, Niimi H, Yanagisawa J, Tanaka T, Kato S 1998 Inactivating mutations in the 25-hydroxyvitamin D3 1{alpha}-hydroxylase gene in patients with pseudovitamin D-deficiency rickets. N Engl J Med 338:653–661[Abstract/Free Full Text]
  14. Inui N, Murayama A, Sasaki S, Suda T, Chida K, Kato S, Nakamura H 2001 Correlation between 25-hydroxyvitamin D3 1 {alpha}-hydroxylase gene expression in alveolar macrophages and the activity of sarcoidosis. Am J Med 110:687–693[CrossRef][Medline]
  15. Robinson BW, McLemore TL, Crystal RG 1985 Gamma interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis. J Clin Invest 75:1488–1495
  16. Moller DR, Forman JD, Liu MC, Noble PW, Greenlee BM, Vyas P, Holden DA, Forrester JM, Lazarus A, Wysocka M, Trinchieri G, Karp C 1996 Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis. J Immunol 156:4952–4960[Abstract]
  17. Minshall EM, Tsicopoulos A, Yasruel Z, Wallaert B, Akoum H, Vorng H, Tonnel AB, Hamid Q 1997 Cytokine mRNA gene expression in active and nonactive pulmonary sarcoidosis. Eur Respir J 10:2034–2039[Abstract]
  18. Hunninghake GW, Gadek JE, Kawanami O, Ferrans VJ, Crystal RG 1979 Inflammatory and immune processes in the human lung in health and disease: evaluation by bronchoalveolar lavage. Am J Pathol 97:149–206[Abstract]
  19. Suda T, Sato A, Ida M, Gemma H, Hayakawa H, Chida K 1995 Hypersensitivity pneumonitis associated with home ultrasonic humidifiers. Chest 107:711–717[Abstract/Free Full Text]
  20. Sone S, Moriguchi S, Shimizu E, Ogushi F, Tsubura E 1982 In vitro generation of tumoricidal properties in human alveolar macrophages following interaction with endotoxin. Cancer Res 42:2227–2231[Abstract/Free Full Text]
  21. Fraser WD, Durham BH, Berry JL, Mawer EB 1997 Measurement of plasma 1,25 dihydroxyvitamin D using a novel immunoextraction technique and immunoassay with iodine labelled vitamin D tracer. Ann Clin Biochem 34:632–637
  22. Haddad JG, Chyu KJ 1971 Competitive protein-binding radioassay for 25-hydroxycholecalciferol. J Clin Endocrinol Metab 33:992–995[Abstract/Free Full Text]
  23. Chomczynski P, Sacchi N 1987 Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156–159[Medline]
  24. Orlowski TM, Szczesny TJ 2001 Surgical treatment of stage III non-small cell lung cancer. Lung Cancer 34(Suppl 2):S137–S143
  25. Bell NH 1998 Renal and nonrenal 25-hydroxyvitamin D-1{alpha}-hydroxylases and their clinical significance. J Bone Miner Res 13:350–353[CrossRef][Medline]
  26. Zehnder D, Bland R, Williams MC, McNinch RW, Howie AJ, Stewart PM, Hewison M 2001 Extrarenal expression of 25-hydroxyvitamin D(3)-1{alpha}- hydroxylase. J Clin Endocrinol Metab 86:888–894[Abstract/Free Full Text]
  27. Provvedini DM, Manolagas SC 1989 1{alpha},25-Dihydroxyvitamin D3 receptor distribution and effects in subpopulations of normal human T lymphocytes. J Clin Endocrinol Metab 68:774–779[Abstract/Free Full Text]
  28. Leung KH 1989 Inhibition of human natural killer cell and lymphokine-activated killer cell cytotoxicity and differentiation by vitamin D3. Scand J Immunol 30:199–208[CrossRef][Medline]
  29. Penna G, Adorini L 2000 1 á,25-Dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 164:2405–2411[Abstract/Free Full Text]
  30. Piemonti L, Monti P, Sironi M, Fraticelli P, Leone BE, Dal Cin E, Allavena P, Di Carlo V 2000 Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J Immunol 164:4443–4451[Abstract/Free Full Text]
  31. Cantorna MT, Woodward WD, Hayes CE, DeLuca HF 1998 1,25-Dihydroxyvitamin D3 is a positive regulator for the two anti-encephalitogenic cytokines TGF-ß 1 and IL-4. J Immunol 160:5314–5319[Abstract/Free Full Text]
  32. Veyron P, Pamphile R, Binderup L, Touraine JL 1993 Two novel vitamin D analogues, KH 1060 and CB 966, prolong skin allograft survival in mice. Transpl Immunol 1:72–76[CrossRef][Medline]
  33. Johnsson C, Binderup L, Tufveson G 1996 Immunosuppression with the vitamin D analogue MC 1288 in experimental transplantation. Transplant Proc 28:888–891[Medline]
  34. Elgert KD, Alleva DG, Mullins DW 1998 Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol 64:275–290[Abstract]
  35. Kiessling R, Wasserman K, Horiguchi S, Kono K, Sjoberg J, Pisa P, Petersson M 1999 Tumor-induced immune dysfunction. Cancer Immunol Immunother 48:353–362[CrossRef][Medline]
  36. Zea AH, Curti BD, Longo DL, Alvord WG, Strobl SL, Mizoguchi H, Creekmore SP, O’Shea JJ, Powers GC, Urba WJ 1995 Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res 1:1327–1335[Abstract]
  37. Tartour E, Latour S, Mathiot C, Thiounn N, Mosseri V, Joyeux I, D’Enghien CD, Lee R, Debre B, Fridman WH 1995 Variable expression of CD3-{zeta} chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: relationship with TIL phenotype and function. Int J Cancer 63:205–212[Medline]
  38. Kono K, Ressing ME, Brandt RM, Melief CJ, Potkul RK, Andersson B, Petersson M, Kast WM, Kiessling R 1996 Decreased expression of signal-transducing {zeta} chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin Cancer Res 2:1825–1828[Abstract]
  39. Whiteside TL 1999 Signaling defects in T lymphocytes of patients with malignancy. Cancer Immunol Immunother 48:346–352[CrossRef][Medline]
  40. Horiguchi S, Petersson M, Nakazawa T, Kanda M, Zea AH, Ochoa AC, Kiessling R 1999 Primary chemically induced tumors induce profound immunosuppression concomitant with apoptosis and alterations in signal transduction in T cells and NK cells. Cancer Res 59:2950–2956[Abstract/Free Full Text]
  41. Murayama A, Takeyama K, Kitanaka S, Kodera Y, Kawaguchi Y, Hosoya T, Kato S 1999 Positive and negative regulations of the renal 25-hydroxyvitamin D3 1{alpha}-hydroxylase gene by parathyroid hormone, calcitonin, and 1á,25(OH)2D3 in intact animals. Endocrinology 140:2224–2231[Abstract/Free Full Text]
  42. Koeffler HP, Reichel H, Bishop JE, Norman AW 1985 ã-Interferon stimulates production of 1,25-dihydroxyvitamin D3 by normal human macrophages. Biochem Biophys Res Commun 127:596–603[CrossRef][Medline]
  43. Reichel H, Koeffler HP, Barbers R, Norman AW 1987 Regulation of 1,25-dihydroxyvitamin D3 production by cultured alveolar macrophages from normal human donors and from patients with pulmonary sarcoidosis. J Clin Endocrinol Metab 65:1201–1209[Abstract/Free Full Text]
  44. Reichel H, Koeffler HP, Norman AW 1987 Synthesis in vitro of 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3 by interferon-{gamma}-stimulated normal human bone marrow and alveolar macrophages. J Biol Chem 262:10931–10937[Abstract/Free Full Text]
  45. Reichel H, Koeffler HP, Bishop JE, Norman AW 1987 25-Hydroxyvitamin D3 metabolism by lipopolysaccharide-stimulated normal human macrophages. J Clin Endocrinol Metab 64:1–9[Abstract/Free Full Text]
  46. Pryke AM, Duggan C, White CP, Posen S, Mason RS 1990 Tumor necrosis factor-{alpha} induces vitamin D-1-hydroxylase activity in normal human alveolar macrophages. J Cell Physiol 142:652–656[CrossRef][Medline]



This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
W. Zhou, R. Suk, G. Liu, S. Park, D. S. Neuberg, J. C. Wain, T. J. Lynch, E. Giovannucci, and D. C. Christiani
Vitamin D Is Associated with Improved Survival in Early-Stage Non-Small Cell Lung Cancer Patients
Cancer Epidemiol. Biomarkers Prev., October 1, 2005; 14(10): 2303 - 2309.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Townsend, C. M. Banwell, M. Guy, K. W. Colston, J. L. Mansi, P. M. Stewart, M. J. Campbell, and M. Hewison
Autocrine Metabolism of Vitamin D in Normal and Malignant Breast Tissue
Clin. Cancer Res., May 1, 2005; 11(9): 3579 - 3586.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
D. Somjen, Y. Weisman, F. Kohen, B. Gayer, R. Limor, O. Sharon, N. Jaccard, E. Knoll, and N. Stern
25-Hydroxyvitamin D3-1{alpha}-Hydroxylase Is Expressed in Human Vascular Smooth Muscle Cells and Is Upregulated by Parathyroid Hormone and Estrogenic Compounds
Circulation, April 5, 2005; 111(13): 1666 - 1671.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yokomura, K.
Right arrow Articles by Nakamura, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yokomura, K.
Right arrow Articles by Nakamura, H.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals